News

Incredible! – The Plausibility Threshold for the Technical Effect is Raised by the EPO – T488/16

Last week saw the revocation of Bristol-Myers Squibb’s (BMS) European patent no. 1169038, which claimed the $1.6 billion a year anti-cancer drug dasatinib, aka Sprycel®. GJE partner, Arnie Clarke, who was representing an opponent in these proceedings, explains the decision and its potentially far-reaching consequences. Background and Issues The patent...

Read more

Recognition for GJE’s Trade Mark partners by World Trademark Review

We are delighted to report that the 2017 edition of World Trademark Review recognises the strength of our trade mark team, which it describes as “brilliant” and the quality and experience of our two partners – Alasdair MacQuarrie and Rowena Price. The Review quotes: “London and Munich trademark attorney firm...

Read more

GJE is a Silver Partner at Biotech and Money London 2017

We are delighted to be a Silver Partner of the third annual Biotech and Money London 2017, which runs from 7-8 February 2017. Biotech and Money is a two-day congress helping build linkages and business opportunities for UK life science companies, capital and partners. The event will bring together 400...

Read more

UK to ratify Unified Patent Court Agreement

The UK government has announced that it will press ahead with plans for ratification of the Unified Patent Court Agreement (UPCA), which is necessary to allow the coming into force of provisions relating to both the new European patent with unitary effect throughout participating EU Member States, and the new...

Read more

Poisonous priority – less toxic now? Enlarged Board issues order in G1/15

The EPO’s Enlarged Board of Appeal has issued their answer to the questions referred to it concerning partial priority in referral G1/15. The answer is: “Under the EPC, entitlement to partial priority may not be refused for a claim encompassing alternative subject-matter by virtue of one or more generic expressions...

Read more